1. Background {#sec1}
=============

Gastric cancer is the fourth most common cancer in the world, and the second most common cause of cancer-related death, affecting approximately 736,000 people in 2008 \[[@B1]\]. Gastric cardia cancer is reportedly increasing in Western countries \[[@B2], [@B3]\]. Gastric cancers with epicenters in the proximal stomach within 5 cm from esophagogastric junction (EGJ) and crossing EGJ are categorized as esophageal cancers by the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) Cancer Staging Manual \[[@B4], [@B5]\]. AJCC/UICC also categorizes any gastric cardia cancer without EGJ invasion as gastric cancer regardless of its location. On the other hand, Siewert\'s classification is widely used as classification for EGJ cancer (EGJC) \[[@B6], [@B7]\]. Siewert\'s classification defines gastric cardia adenocarcinoma with its epicenter in the proximal 2 cm of the stomach as type II; subcardial gastric adenocarcinoma with its epicenter in the proximal 5 cm of the stomach, which infiltrates the EGJ and distal esophagus, as type III. Thus, adenocarcinomas with epicenters in the proximal 5 cm of the stomach were defined as type II or III if they infiltrated the EGJ. Siewert et al. also advised that subtotal esophagectomy had less survival effectiveness for patients with type II adenocarcinoma \[[@B8]\]. Therefore, EGJ invasion is an important factor in diagnosis and treatment for gastric cardia cancer.

The aim of this study was to clarify the differences in clinicopathological characteristics in patients with gastric cardia cancer with or without EGJ invasion and to investigate optimal clinical management of gastric cardia cancer.

2. Methods {#sec2}
==========

2.1. Study Design {#sec2.1}
-----------------

We retrospectively studied patients who underwent curative surgery, including lymph node dissection, for gastric cardia and subcardial cancers at the Digestive Disease Center, Showa University Northern Yokohama Hospital between October 2001 and December 2010. Clinical and histological data and prognoses were determined based on medical records.

2.2. Patients {#sec2.2}
-------------

Patients who underwent curative surgery for gastric cardia or subcardial cancer were included in this study. Inclusion criteria were (i) presence of histologically proven carcinoma of the upper-third of the stomach; (ii) histologically solitary tumors; (iii) no prior treatment by endoscopic resection, chemotherapy, or radiation therapy. Exclusion criteria were (i) presence of synchronous or metachronous malignancy; (ii) presence of severe organ dysfunction. All disease was pathologically staged using the AJCC/UICC TNM Cancer Staging Manual (7th ed.). All patient data were approved for use by the institutional review board of Showa University Northern Yokohama Hospital. This study was registered with the University Hospital Medical Information Network in Japan, number UMIN000008774.

2.3. Classification {#sec2.3}
-------------------

Any gastric cancer entered in the proximal 5 cm of the stomach with EGJ invasion is defined as esophageal cancer by the AJCC/UICC, whereas any cancer near the EGJ without EGJ invasion is defined as gastric cancer. Thus, we categorized tumors centered in the proximal 5 cm of the stomach into two types, according to presence of EGJ invasion. Categorization criteria were (i) any histological carcinoma centered in the stomach within 5 cm from EGJ, with EGJ invasion (type Ge); (ii) any histological carcinoma centered in the stomach within 5 cm from EGJ, without EGJ invasion (type G). Type Ge tumors were staged using both esophageal cancer and gastric cancer staging manuals.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analysis was performed using JMP Statistical Discovery 9.0.3 (SAS Institute, Cary, USA). Fisher\'s exact test and *χ* ^2^ test were used to compare characteristics of patients. The nonparametric Mann-Whitney test was used to assess differences in age and tumor size. Kaplan-Meier curves of estimated overall survival were generated and compared between the groups using a 2-sided log-rank test. To investigate prognostic factors, Cox proportional hazard analysis was used. *P* values \<0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. Clinicopathological Characteristics {#sec3.1}
----------------------------------------

A total of 80 patients were eligible and studied. Median follow-up period of the surviving patients was 32.5 months. Clinicopathological characteristics of the patients are summarized in [Table 1](#tab1){ref-type="table"}. Tumor characteristics were described using AJCC/UICC TNM classifications. Approximately 76% of patients were men; their average age was 67.6 years (range: 35--90 years). Thirty-one (38.8%) and 49 (61.3%) patients underwent proximal gastrectomies and total gastrectomies, respectively. Histologically, all 80 tumors were adenocarcinoma. Twenty-six of 80 patients had tumors with esophageal invasion (type Ge tumor). The mean number of dissected lymph nodes was 38.3 ± 29.9 (SD) in each patient. Thirty-five (43.8%) of the 80 patients had lymph node metastases (pN1--3). Thirty-two (40.0%), 21 (26.3%), 12 (15.0%), and 15 (18.8%) patients were pathologically staged I, II, III, and IV, respectively.

Comparison of clinicopathological characteristics between type Ge and G tumor groups are summarized in [Table 2](#tab2){ref-type="table"}. There were significant differences in pathological tumor size, distance between EGJ and tumor center, lymphatic invasion, venous invasion, depth of tumor invasion (pT category), lymph node metastasis (pN category), distant metastasis (pM category) and TNM stage. Patients with Type G tumors tended to have earlier-stage diseases.

Incidence of lymph node metastases is summarized in [Table 3](#tab3){ref-type="table"}. Nineteen (73.1%) of 26 type Ge tumors and 16 (29.6%) of 54 type G tumors had lymph nodes metastases (*P* \< 0.001). Although incidence of nodal metastasis in pT1 tumors was significantly higher in the type Ge tumor group than the type G tumor groups, there was no significant difference in pT2, pT3, and pT4 tumors between two tumor groups. No nodal metastases in the cervical lymph node were seen in the type Ge and G tumor groups. Only two patients in type Ge tumor group had mediastinal lymph node metastases (lower thoracic and esophageal hiatal paraesophageal lymph node). Two patients with mediastinal lymph node metastases died. One patient had disease recurrence (peritoneal dissemination), and the other patient died from surgical complication (pneumonia). Incidence of perigastric lymph node metastasis were significantly higher in the type Ge tumor group than in the type G tumor group (*P* = 0.002). In perigastric lymph nodes, the type Ge tumor group had a significantly higher incidence of nodal metastasis at left paracardial (*P* = 0.004), right paracardial (*P* = 0.006), and lesser curvature (*P* = 0.028) lymph nodes. Suprapyloric and infrapyloric lymph nodes metastases were rare in both tumor groups. Type Ge tumor group also had significantly higher incidence of nodal metastasis at the splenic hilum (*P* = 0.032).

3.2. Staging Controversy in Gastric Cardia and Subcardial Cancers That Cross the Esophagogastric Junction {#sec3.2}
---------------------------------------------------------------------------------------------------------

Although the usual tumor location of type Ge tumors is in the stomach, AJCC/UICC Cancer Staging Manual defines type Ge tumors as esophageal cancer. We investigated discrepancies between disease stages by the AJCC/UICC TNM gastric cancer and esophageal cancer staging manual (7th ed.). The stage discrepancy was visualized in [Figure 1](#fig1){ref-type="fig"}. Type Ge tumors tended to be staged into progressive disease by esophageal cancer staging manual. Two of 5 in pStage I, 3 of 7 pStage II, and 9 of 11 pStage III patients staged by gastric cancer staging manual were changed more progressive disease by esophageal cancer staging manual.

3.3. Surgical Outcomes {#sec3.3}
----------------------

The 5-year overall survival rate was 57.3%. Twenty-five patients had recurrent diseases (peritoneum: 11; lymph nodes: 9; liver: 3; lung: 3; bone: 1; adrenal gland: 1; anastomosis: 1), and 24 patients died. Eighteen, 1, and 5 of 24 patients died of cancer, surgical complication, and other causes. Overall survival rates were compared between the patients with type G and Ge tumors. In patients with pT1--4 tumors, although not significantly, the type G tumor group had a higher survival rate (5-year overall survival rate, 64.9%) than the type Ge tumor group (5-year overall survival rate, 49.0%) (*P* = 0.071; [Figure 2(a)](#fig2){ref-type="fig"}). Next, type Ge tumor group was staged by both esophageal and gastric cancer staging manuals. In stages I-II patients, type G tumor group had higher survival rate; however; there was no significance (*P* = 0.376). Although there was no significant difference, survival rate of type Ge tumor group staged by gastric cancer staging manual was superior to those staged by esophageal cancer staging manual. In stage III-IV patients, three patient groups (type G tumor group, type Ge tumor group staged by esophageal cancer staging manual, and type Ge tumor group staged by gastric cancer staging manual) had similar survival curves (*P* = 0.780) ([Figure 2(b)](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

The aim of this study was to clarify the clinicopathological differences between gastric cardia cancer with and without esophageal invasion. Gastric cardia cancers with esophageal and EGJ invasion have been treated as EGJC \[[@B9]\] or gastric \[[@B10]\] cancer. However, AJCC/UICC TNM Cancer Staging Manual (7th ed.) defined tumors centered in the proximal 5 cm of the stomach that cross the EGJ as esophageal cancer \[[@B4], [@B5]\]; therefore, we staged those using the esophageal cancer staging manual.

Siewert et al. argued that complete surgical resection and lymph node metastasis were independent prognostic factors in EGJC, and subtotal esophagectomy had less survival effectiveness for the patients with type II adenocarcinoma \[[@B8]\]. Hasegawa et al. reported that about 60% and 90% of patients with type II and III tumors, respectively, had lymph node metastases and recommended complete resection for improving survival \[[@B11]\]. Schiesser et al. reported that extended total gastrectomy should be performed for type II-III tumors \[[@B12]\]. With regard to surgical approach, Sasako et al. showed that the left thoracoabdominal approach did not improve survival after the abdominal-transhiatal approach and leads to increased morbidity in patients with cancer of the cardia or subcardia \[[@B13]\]. Carboni et al. maintained effects of extended gastrectomy by an abdominal-transhiatal approach for EGJC \[[@B14]\].

We studied any tumor centered in the proximal 5 cm of the stomach, and simply categorized them in 2 groups including types Ge and G according to the presence of EGJ invasion. Whereas there were significantly differences in patients background between type Ge and G tumor groups, type G tumor group showed some differences in clinicopathological characteristics. In lymph node metastasis, approximately 70% and 30% of the patients with type Ge and G tumors, respectively, had lymph node metastases in this study. Although no cervical lymph node metastasis was recognized in either tumor group, lower mediastinal lymph node metastasis was recognized in only the type Ge tumor group. Especially, there was significant difference of incidence of nodal metastasis in left paracardial, right paracardial, and lesser curvature lymph node between two tumor groups. To achieve complete resection, we should perform partial or total gastrectomy and lower esophagectomy with lower mediastinal and abdominal lymphadenectomy for the type Ge tumor. For type G tumor, it was not necessary to perform mediastinal lymphadenectomy because there was no mediastinal lymph node metastasis in the type G tumor group.

Because EGJ invasion generally occurs with tumor progression in gastric cancer, it is reasonable that type Ge tumors have deeper depth of invasion and more widespread nodal metastasis than type G tumors. Additionally, esophageal invasion could increase risk of mediastinal lymph node metastasis. Therefore, the survival rate of patients with type Ge tumor was inferior, but not significantly, to patients with type G tumor.

The AJCC/UICC TNM staging system for esophageal cancer defines nodal metastasis at perigastric lymph nodes (other than the left and right paracardial lymph nodes) as distant metastasis \[[@B4], [@B5]\], although the lymph node along the lesser curvature is a key regional lymph node for gastric cancer. Thus, type Ge tumors tended to be staged into progressive disease by the esophageal cancer staging manual. Interestingly, the survival rate of stage I-II patients staged by the esophageal cancer staging manual was inferior to those staged by the gastric cancer staging manual, whereas the survival rate of stages III-IV patients staged by the esophageal cancer staging manual was similar to those staged by the gastric cancer staging manual. However, as the survival rates of type Ge and G tumor groups did not significantly differ, there is no significant evidence for or against using the AJCC/UICC staging manual for these tumors.

As clinicopathological characteristics and survival between type Ge and G tumor groups differ, it is appropriate to distinguish type Ge with type G tumor; however, it is unclear from this study that we should treat type Ge tumors as esophageal cancer, because this study analyzed too small number of the patients to clarify the validity.

5. Conclusions {#sec5}
==============

Because the AJCC/UICC Cancer Staging Manual categorizes gastric cardia cancer with EGJ invasion as esophageal cancer, EGJ invasion is an important factor in diagnosis and treatment for gastric cardia cancer. We retrospectively studied patients who underwent curative surgery for gastric cardia and subcardial cancers to clarify the differences in clinicopathological characteristics and prognoses in patients with gastric cardia cancer with (type Ge) or without (type G) EGJ invasion. Among patients with pT1 tumor, those with type Ge tumor had significantly higher incidence of lymph node metastasis, whereas mediastinal lymph node metastases were seen in only 2 patients with type Ge tumors.

As patients with Ge tumors staged by either esophageal or gastric cancer staging manuals showed no significant difference in survival rates, it is adequate to distinguish type Ge from type G tumor because of their clinicopathological differences. Therefore, it seems that to regard type Ge tumor as esophageal cancer is adequate.
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![Staging comparison of gastric cardia cancer with esophageal invasion (*n* = 26).](IJSO2013-189459.001){#fig1}

![(a) Overall survival rates were compared between the patients with type G and Ge tumors. In patients with pT1--4 tumors, although not significantly, the type G tumor group had a higher survival rate than the type Ge tumor group (*P* = 0.071). (b) Type Ge tumor group was staged by both esophageal and gastric cancer staging manuals. In stages I-II patients, type G tumor group had higher survival rate; however, there was no significance (*P* = 0.376). Although there was no significant difference, survival rate of type Ge tumor group staged by gastric cancer staging manual was superior to those staged by esophageal cancer staging manual. In stages III-IV patients, three patient groups (type G tumor group, type Ge tumor group staged by esophageal cancer staging manual and type Ge tumor group staged by gastric cancer staging manual) had similar survival curves (*P* = 0.780).](IJSO2013-189459.002){#fig2}

###### 

Clinicopathological characteristics of patients (*n* = 80).

  Variable                                   Number of subject
  ------------------------------------------ -------------------
  Age (year, mean ± SD)                      67.6 ± 10.8
  Sex                                         
   Male                                      61 (76.3%)
   Female                                    19 (23.7%)
  Pathological tumor size (mm, mean ± SD)    46.8 ± 22.7
  Macro type                                  
   Type 0                                    31 (38.8%)
   Type 1                                    4 (5.0%)
   Type 2                                    18 (22.5%)
   Type 3                                    22 (27.5%)
   Type 4                                    1 (1.3%)
   Type 5                                    4 (5.0%)
  Main histological type^†^                   
   Differentiated                            48 (60.0%)
   Undifferentiated                          32 (40.0%)
  Distance between EGJ and tumor epicenter    
   ≤20 mm                                    21 (26.3%)
   \>20 mm                                   59 (73.8%)
  Esophageal invasion                         
   Yes                                       26 (32.5%)
   No                                        54 (67.5%)
  Lymphatic invasion                          
   L0                                        32 (40.0%)
   L1                                        48 (60.0%)
  Venous invasion                             
   V0                                        32 (40.0%)
   V1                                        48 (60.0%)
   V2                                        0
  Depth of tumor invasion                     
   pT1                                       29 (36.3%)
   pT2                                       11 (13.8%)
   pT3                                       26 (32.5%)
   pT4                                       14 (17.5%)
  Lymph node metastasis                       
   pN0                                       45 (56.3%)
   pN1                                       12 (15.0%)
   pN2                                       11 (13.8%)
   pN3                                       12 (15.0%)
  Distant metastasis                          
   M0                                        65 (81.3%)
   M1                                        15 (18.8%)
  TNM stage                                   
   I                                         32 (40.0%)
   II                                        21 (26.3%)
   III                                       12 (15.0%)
   IV                                        15 (18.8%)
  Extent of gastrectomy                       
   Proximal                                  31 (38.8%)
   Total                                     49 (61.3%)
  Surgical approach                           
   Laparoscopic surgery                      30 (37.5%)
   Hand-assisted laparoscopic surgery        17 (21.3%)
   Open surgery                              33 (41.3%)
  Splenectomy                                 
   No                                        56 (70.0%)
   Yes                                       24 (30.0%)
  Thoracotomy                                 
   No                                        74 (92.5%)
   Yes                                       6 (7.5%)
  Postoperative chemotherapy                  
   No                                        45 (56.3%)
   Yes                                       35 (43.8%)

^†^Differentiated: papillary carcinoma, well differentiated adenocarcinoma, moderately differentiated adenocarcinoma; Undifferentiated: poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous adenocarcinoma.

###### 

Comparison of clinicopathological characteristics of patients with gastric cardia cancer with or without esophageal invasion.

  Variable                                   With esophageal invasion (*n* = 26)   Without esophageal invasion (*n* = 54)   *P*-value
  ------------------------------------------ ------------------------------------- ---------------------------------------- -------------
  Age (year, mean ± SD)                      65.3 ± 10.8                           68.6 ± 10.8                              0.271
  Sex                                                                                                                       0.773
   Male                                      19 (73.1%)                            42 (77.8%)                                
   Female                                    7 (26.9%)                             12 (22.2%)                                
  Pathological tumor size (mm, mean ± SD)    61.9 ± 18.9                           39.5 ± 20.8                              \<0.001\*\*
  Main histological type^†^                                                                                                 0.811
   Differentiated                            15 (57.7%)                            33 (61.1%)                                
   Undifferentiated                          11 (42.3%)                            21 (38.9%)                                
  Distance between EGJ and tumor epicenter                                                                                  \<0.001\*\*
   ≤20 mm                                    15 (57.7%)                            6 (11.1%)                                 
   \>20 mm                                   11 (42.3%)                            48 (88.9%)                                
  Lymphatic invasion                                                                                                        0.003\*\*
   L0                                        4 (15.4%)                             28 (51.9%)                                
   L1                                        22 (84.6%)                            26 (48.2%)                                
  Venous invasion                                                                                                           \<0.001\*\*
   V0                                        3 (11.5%)                             29 (53.7%)                                
   V1                                        23 (88.5%)                            25 (46.3%)                                
  Depth of tumor invasion                                                                                                   0.028\*
   pT1                                       4 (15.4%)                             25 (46.3%)                                
   pT2                                       3 (11.5%)                             8 (14.8%)                                 
   pT3                                       13 (50.0%)                            13 (24.1%)                                
   pT4                                       6 (23.1%)                             8 (14.8%)                                 
  Lymph node metastasis                                                                                                     0.002\*\*
   pN0                                       7 (26.9%)                             38 (70.4%)                                
   pN1                                       6 (23.1%)                             6 (11.1%)                                 
   pN2                                       5 (19.2%)                             6 (11.1%)                                 
   pN3                                       8 (30.8%)                             4 (7.4%)                                  
  Distant metastasis                                                                                                        0.010\*
   M0                                        11 (42.3%)                            54 (100%)                                 
   M1                                        15 (57.7%)                            0                                         
  TNM stage                                                                                                                 \<0.001\*\*
   I                                         3 (11.5%)                             29 (53.7%)                                
   II                                        6 (23.1%)                             15 (27.8%)                                
   III                                       2 (7.7%)                              10 (18.5%)                                
   IV                                        15 (57.7%)                            0                                         
  Extent of gastrectomy                                                                                                     0.150
   Proximal                                  7 (26.9%)                             24 (44.4%)                                
   Total                                     19 (73.1%)                            30 (55.6%)                                
  Surgical approach                                                                                                         0.037\*
   Laparoscopic surgery                      6 (23.1%)                             24 (44.4%)                                
   Hand-assisted laparoscopic surgery        4 (15.4%)                             13 (24.1%)                                
   Open surgery                              16 (61.5%)                            17 (31.5%)                                
  Splenectomy                                                                                                               \<0.001\*\*
   No                                        9 (34.6%)                             47 (87.0%)                                
   Yes                                       17 (65.4%)                            7 (13.0%)                                 
  Thoracotomy                                                                                                               0.013\*
   No                                        21 (80.8%)                            53 (98.2%)                                
   Yes                                       5 (19.2%)                             1 (1.9%)                                  
  Postoperative chemotherapy                                                                                                0.002\*\*
   No                                        8 (30.8%)                             37 (68.5%)                                
   Yes                                       18 (69.2%)                            17 (31.5%)                                

\**P* \< 0.05, \*\**P* \< 0.01.

^†^Differentiated: papillary carcinoma, well differentiated adenocarcinoma, moderately differentiated adenocarcinoma; Undifferentiated: poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous adenocarcinoma.

###### 

Comparison of lymph node metastasis in patients with gastric cardia cancer, with or without esophageal invasion.

  Variable                   With esophageal invasion (*n* = 26)   Without esophageal invasion (*n* = 54)   *P*-value
  -------------------------- ------------------------------------- ---------------------------------------- -----------
  Overall                    19 (73.1%)                            16 (29.6%)                               \<0.001∗∗
  Depth of tumor invasion                                                                                    
   pT1                       2/4 (50.0%)                           0/15                                     0.035\*
   pT2                       2/3 (66.7%)                           4/8 (50.0%)                              0.576
   pT3                       9/13 (69.2%)                          7/13 (53.8%)                             0.344
   pT4                       6/6 (100%)                            5/8 (62.5%)                              0.154
  Location of lymph node                                                                                     
   Cervical LN               0                                     0                                        ---
   Mediastinal LN            2 (7.7%)                              0                                        0.103
   Perigastric LN            17 (65.4%)                            15 (27.8%)                               0.002\*\*
    Left paracardial         8 (30.8%)                             3 (5.6%)                                 0.004\*\*
    Right paracardial        10 (38.5%)                            6 (11.1%)                                0.006\*\*
    Lesser curvature         12 (46.2%)                            12 (22.2%)                               0.028\*
    Greater curvature        4 (15.4%)                             2 (3.7%)                                 0.100
    Suprapyloric             0                                     1 (1.9%)                                 0.675
    Infrapyloric             1 (3.8%)                              0                                        0.325
   Left gastric artery       4 (15.4%)                             7 (13.0%)                                0.508
   LN at Celiac trunk        1 (3.8%)                              2 (3.7%)                                 0.698
   LN along hepatic artery   2 (7.7%)                              1 (1.9%)                                 0.245
   LN along splenic artery   3 (11.5%)                             1 (1.9%)                                 0.098
   LN at splenic hilum       3 (11.5%)                             0                                        0.032\*

\**P* \< 0.05, \*\**P* \< 0.01.
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